Skip to main content
Equibles
AUPH logo

AUPH · Aurinia Pharmaceuticals Inc. · Webcasts, Transcripts & Audio

Track AUPH — free

Use AUPH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AUPH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.78 -0.05 (-0.32%)
Russell 2000 member Rebalance outlook locked
Market Cap
$2.18B
Shares
133.05M
Volume · Oct 5 394.22K Avg daily vol (3M) 1.06M

Aurinia Pharmaceuticals Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Aurinia Pharmaceuticals Inc. (AUPH), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲2266% $21.62M −$37.63M '22 Q1 22-05-10 ▲325.8% $28.19M −$35.52M '22 Q2 22-08-04 ▲280.3% $55.78M −$8.99M '22 Q3 22-11-03 ▲21.5% $28.43M −$26.05M '22 Q4 23-02-28 ▲59.1% $34.41M −$26.21M '23 Q1 23-05-04 ▲47.2% $41.49M −$11.49M '23 Q2 23-08-03 ▼2.3% $54.52M −$13.45M '23 Q3 23-11-02 ▲58.6% $45.09M −$26.88M '23 Q4 24-02-15 ▲46.2% $50.30M −$10.75M '24 Q1 24-03-31 ▲37.8% $57.19M $722,000 '24 Q2 24-08-01 ▲24.3% $67.77M $14.35M '24 Q3 24-11-07 ▲32.8% $59.87M $1.43M '24 Q4 25-02-27 ▲24.2% $62.47M $23.34M '25 Q1 25-06-30 ▲22.4% $70.01M $21.51M '25 Q2 25-07-31 ▲8.4% $73.47M $31.55M '25 Q3 25-11-04 LATEST ▲28.8% $77.11M $210.79M '25 Q4 26-02-26
Earnings call
FY25 · Q4
2026-02-26
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
Confident tone Diagnostic and treatment paradigm strategy Combination therapy research Aritintercept pipeline development
Revenue
$77.11M
▲ 28.8% YoY
Diluted EPS
$1.53
▲ 15200% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2025 Earnings Call Transcript
Confident tone Aritinercept development LUPKYNIS commercial growth Raised 2025 financial guidance
Revenue
$73.47M
▲ 8.4% YoY
Diluted EPS
$0.23
▲ 130% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript
Confident tone Revenue and earnings momentum LUPKYNIS commercial growth Aritinercept (AUR200) pipeline
Revenue
$70.01M
▲ 22.4% YoY
Diluted EPS
$0.16
▲ 1500% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-06-30
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript
Confident tone LUPKYNIS commercial growth AUR200 pipeline (Phase 1 SAD) ACR/EULAR/KDIGO guidelines and first-line positioning
Revenue
$62.47M
▲ 24.2% YoY
Diluted EPS
$0.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call
Confident tone AUR200 pipeline development 2025 financial guidance LUPKYNIS revenue growth
Revenue
$59.87M
▲ 32.8% YoY
Diluted EPS
$0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2024 Earnings Call Transcript
Positive tone LUPKYNIS commercial performance Japan regulatory approval and Otsuka partnership ENLIGHT-LN registry and real-world evidence
Revenue
$67.77M
▲ 24.3% YoY
Diluted EPS
$0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2024 Earnings Call Transcript
Confident tone Revenue and commercial growth AUR200 pipeline development Otsuka partnership and international expansion
Revenue
$57.19M
▲ 37.8% YoY
Diluted EPS
$0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Call Transcript
Confident tone Pipeline development (AUR200 and AUR300) Lupus nephritis market opportunity and awareness LUPKYNIS commercial performance
Revenue
$50.30M
▲ 46.2% YoY
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2023 Earnings Call Transcript
Positive tone Patient growth metrics LUPKYNIS commercial performance Physician and patient education
Revenue
$45.09M
▲ 58.6% YoY
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2023 Earnings Call Transcript
Revenue
$54.52M
▼ 2.3% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2023 Earnings Call Transcript
Revenue
$41.49M
▲ 47.2% YoY
Diluted EPS
$-0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2023 Earnings Call Transcript
Revenue
$34.41M
▲ 59.1% YoY
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2022 Earnings Call Transcript
Revenue
$28.43M
▲ 21.5% YoY
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2022 Earnings Call Transcript
Revenue
$55.78M
▲ 280.3% YoY
Diluted EPS
$-0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2022 Earnings Call Transcript
Revenue
$28.19M
▲ 325.8% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2022 Earnings Call Transcript
Revenue
$21.62M
▲ 2266% YoY
Diluted EPS
$-0.27
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2021 Earnings Call Transcript
Revenue
$23.40M
▼ 53.2% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2021 Earnings Call Transcript
Revenue
$14.67M
▲ 50475.9% YoY
Diluted EPS
$-0.39
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2021 Earnings Call Transcript
Revenue
$6.62M
▲ 22727.6% YoY
Diluted EPS
$-0.37
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2021 Earnings Call Transcript
Revenue
$914,000
▲ 2946.7% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2020 Earnings Call Transcript
Revenue
$50.03M
▲ 172417.2% YoY
Diluted EPS
$-0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2020 Earnings Call Transcript
Revenue
$29,000
▼ 87.4% YoY
Diluted EPS
$-0.34
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2020 Earnings Call Transcript
Revenue
$29,000
▲ 0% YoY
Diluted EPS
$-0.24
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2020 Earnings Call Transcript
Revenue
$30,000
▲ 0% YoY
Diluted EPS
$-0.23
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 webcasts
Key facts CIK 1600620 CUSIP 05156V102 13F (30d) 4 filings 4 filers Visit website Investor relations